等待開盤 03-26 09:30:00 美东时间
+3.640
+7.48%
Grail (GRAL) shares spiked on Wednesday after TD Cowen upgraded the Galleri cancer test maker to Buy from Hold, citing an attractive buying opportunity following its recent sell-off. The Illumina (ILM...
03-19 01:10
BUZZ-Grail rises after TD Cowen upgrade ** Shares of diagnostics firm Grail GRAL.O rise 4.2% to $49.36 premarket ** Brokerage TD Cowen upgrades GRAIL to “buy” from “hold”, but cuts its price target to $65 from $114 ** TD Cowen says the recent sell-off after the NHS Galleri trial miss has created an
03-18 17:51
Cancer test developer Grail (GRAL) has named Josh Ofman, the company's president, as its new chief executive officer, effective June 1, 2026, following the retirement of its long-serving CEO, Bob Ragu...
03-13 19:48
华盛资讯3月13日讯,Grail公布2025财年年度业绩,公司年度营收1.47亿美元,同比增长17.2%,归母净利润亏损4.08亿美元,同比亏损缩窄79.9%。
03-13 06:32
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board
03-13 04:33
Broad Arrow Auctions held its most successful auction to date at the 2026 Amelia Concours Auction, with total sales exceeding $107 million. The 1972 Lamborghini Miura P400 SV set a new world record, selling for $6,605,000, surpassing previous Miura auction records by over $1.7 million.其他亮点包括2001 RUF RGT以33.5万美元和2015 Ferrari 458 Speciale以91.25万美元成交。私人收藏中的90和2000年代现代收藏品以及战前和战后美国和欧洲汽车表现突出,使Broad Arrow在市场各个领域都取得了强劲的价格和额外的记录。
03-07 22:15
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 4, 2026 /PRNewswire/ -- Grail, Inc. (NAS...
03-05 03:15
今日重点评级关注:花旗:维持Telix Pharmaceuticals"买入"评级,目标价从22美元升至22.5美元;摩根士丹利:维持Vir Biotechnology"超配"评级,目标价从20美元升至24美元
02-25 11:03
Morgan Stanley analyst Tejas Savant maintains GRAIL (NASDAQ:GRAL) with a Equal-Weight and lowers the price target from $110 to $60.
02-25 01:31
GRAIL stock tumbles after NHS-Galleri trial misses main goal, despite a drop in late-stage cancer cases.
02-23 22:29